Equillium, Inc. — Q1 2023 Form 10-Q
Reporting period: Three months ended March 31, 2023. Equillium is a clinical-stage biotechnology company developing therapies for severe autoimmune and inflammatory diseases. It has no approved products and has not generated product sales; Q1 revenue came from its Ono agreement.
Financial performance and position
| Metric | Q1 2023 | Q1 2022 |
|---|---|---|
| Revenue | $8.9 million | $0 |
| Research and development | $9.3 million | $10.8 million |
| General and administrative | $3.7 million | $3.5 million |
| Net loss | $3.9 million | $37.4 million |
| Net loss per share, basic and diluted | $0.11 | $1.17 |
| Cash used in operating activities | $8.0 million | $12.1 million |
- Revenue composition: $6.7 million of Ono-funded development costs and $2.2 million recognized from the upfront option payment. No product, milestone, or royalty revenue was reported.
- Liquidity: Cash and cash equivalents were $24.5 million and short-term investments were $37.5 million, totaling $62.0 million at March 31, 2023. Current assets were $70.2 million versus current liabilities of $32.0 million.
- Debt: Notes payable had a $7.6 million carrying value, including $5.7 million current and $1.8 million long-term. The term loan matures June 1, 2024; the company reported covenant compliance.
- Equity and accumulated losses: Stockholders’ equity was $29.3 million; accumulated deficit was $176.3 million. Shares outstanding were 34,414,149.
- Operating cash use improved year over year, principally because the company received $5.9 million of Ono development funding. Cash and cash equivalents fell by $34.6 million, substantially reflecting net purchases of short-term investments; investing cash outflow was $25.2 million.
Material changes versus the prior period
- Revenue increased from zero to $8.9 million, reflecting the Ono agreement.
- Net loss declined to $3.9 million from $37.4 million. The prior-year quarter included $23.0 million of acquired in-process R&D expense related to the Bioniz asset acquisition; no such charge was recorded in Q1 2023.
- R&D expense decreased $1.5 million, mainly due to lower employee costs, Australian research tax incentive benefits, and non-clinical and acquisition-related costs, partly offset by increased clinical development spending.
- Interest income increased to $0.6 million from $25,000, while other income turned to a $0.2 million expense, primarily from foreign-currency losses.
Outlook, agreements, and risks
- Management stated that the March 31 cash, cash equivalents, and short-term investments were expected to fund planned operations into 2025; the filing also states these resources should cover at least the next 12 months from filing. The company expects continuing losses and may need additional financing. No product-sale revenue is expected in the next 12 months, if ever.
- Ono paid an upfront amount of approximately $26.4 million for an option to acquire Equillium’s itolizumab rights in the United States, Canada, Australia, and New Zealand. If exercised, the option payment would be approximately $37.2 million, with up to $101.4 million in potential development and commercialization milestones. Ono funds development costs during the option period. The option period is tied to clinical data from the EQUALISE lupus nephritis study and the EQUATOR Phase 3 acute graft-versus-host disease study; Ono may terminate in specified circumstances, and exercise or milestone payments are not assured.
- Active development includes EQ101 in alopecia areata, EQ102 in a first-in-human study, and itolizumab in a Phase 3 aGVHD study and lupus nephritis study. Equillium also co-funds Biocon’s Phase 2 ulcerative colitis study of itolizumab.
- Key risks include clinical trial failure or delay, financing needs and potential dilution, dependence on Ono and Biocon, manufacturing and CRO reliance, regulatory and intellectual-property uncertainty, and foreign-exchange and market volatility.
- Equillium reported full access to its funds after the March 2023 SVB receivership; approximately $8.2 million held in an SVB sweep account became accessible on March 13. The company noted possible future financing or loan-related effects.
- On April 5, 2023, Nasdaq notified the company that its share price did not meet the $1 minimum bid requirement. The stated initial compliance deadline was October 2, 2023; delisting remained a risk if compliance was not regained.
- The company reported no legal proceedings and concluded disclosure controls were effective as of March 31, 2023. Management reported no material change in internal control over financial reporting during the quarter.
Investor facts to verify
- Whether Ono exercises its itolizumab option, and the timing and terms of any future funding, option fee, or milestone receipts.
- Clinical progress, enrollment, safety findings, and timing of data from EQUATOR, EQUALISE, and EQ101/EQ102 studies.
- Cash burn and runway assumptions, including whether the stated funding into 2025 remains supportable as trial costs change.
- Loan repayment schedule, lender covenants, and any financing restrictions or need for additional capital.
- Nasdaq bid-price compliance and any subsequent listing-status developments.